THE MEDICAMENTAL TREATMENT OF GLAUCOMA IN THE PATIENTS PRESENTING WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE


Cite item

Full Text

Abstract

This review is aimed at the analysis of the literature data concerning the action of pharmaceutical products for the treatment of glaucoma on the respiratory function of the patients presenting with chronic obstructive pulmonary disease. The beta-adrenergic blocking agents that are at present extensively used to manage hypertension are known to deteriorate the respiratory function not only in the patients with chronic broncho-obstructive pathology but also in the elderly patients having no pulmonary problems in their medical histories. It is concluded that the patients presenting with confirmed or suspected chronic obstructive pulmonary disease should be treated with prostaglandin analogs and local carbonic anhydrase inhibitors.

About the authors

I. B Alekseev

ГБОУ ДПО «Российская медицинcкая академия последипломного образования

, д-р мед. наук, проф. каф. офтальмологии Российской медицинской академии последипломного образования

I. I Shteiner

Региональный медицинский центр, Самара

аспирант каф. офтальмологии Российской медицинской академии последипломного образования.

References

  1. Алексеев В.Н., Мартынова Е.Б. Новые подходы к гипотензивной терапии первичной открытоугольной глаукомы // Consilium Medicum. - 2001. - Прил. - С. 3-9.
  2. Егоров Е.А. Нежелательные явления гипотензивной терапии глаукомы. /Клин. офтальмол. - 2007. -Том 8, № 4. - С. 144-147.
  3. Егоров Е.А., Егорова Т.Е., Оганезова Ж.Г. Российский клинический опыт по изучению эффективности и безопасности 0,004% раствора травопроста (Траватан) в лечении открытоугольной глаукомы/Клин. офтальмол. - 2005. - № 3. - С. 118-123.
  4. Егоров Е.А., Астахов Ю.С., Ставицкая Т.В. Офтальмофармакология. 3-е изд. - М., 2009.
  5. Курышева Н.И. Бетаксолол в лечении глаукомы / Глаукома. - 2006. -№ 2. - С. 73-76.
  6. Марченков Я.В. Лечение артериальной гипертензии у больных с бронхиальной астмой и ХОБЛ // Атмосфера. Пульмонол. и аллергол. - 2002. - № 2 (5). - С. 28-29.
  7. Национальное руководство по глаукоме: для практикующих врачей / Под ред. Е.А. Егорова, Ю.С. Астахова, А.Г. Щуко. -2-е изд. - М., 2011.
  8. Офтальмология: Клинические рекомендации / Под ред. Л.К. Мошетовой, А.П. Нестерова, Е.А. Егорова. - 2-е изд. - М., 2009.
  9. Рациональная фармакотерапия в офтальмологии: Руководство для практикующих врачей / Под общ. ред. Е.А. Егорова. - М., 2011.
  10. Чучалин А.Г. Клинические рекомендации: Хроническая обструктивная болезнь легких. - М., 2007.
  11. Чучалин А.Г. Хроническая обструктивная болезнь легких и сопутствующие заболевания. Часть I. ХОБЛ и поражения сердечно-сосудистой системы / Рус. мед. журн. — 2009. — Т. 16, № 2. — С. 58-64.
  12. Чугаева И.И., Орлова Н.П. Бронхообструктивный синдром/ Лечеб. дело. - 2008. - № 2. - С. 27-31.
  13. Шмелев Е.И. Бронхиальная обструкция при болезнях органов дыхания и бронходилатирующие средства // Пульмонология. - 2006. - № 6. - С. 112-117.
  14. Шмелев Е.И. Бронхообструктивный синдром - универсальное патологическое состояние в пульмонологии. // Атмосфера. Пульмонол. аллергол. - 2006. - № 1. - С. 3-8.
  15. Avorn J., Glynn R.J., Gurwitz J.H. et al. Adverse pulmonary effects of topical Beta blockers used in the treatment of glaucoma. // J. Glaucoma. - 1993. - Vol. 2, N 3. - P. 158-165.
  16. Becker-Shaffer’s Diagnosis and Therapy of the Glaucomas. - 8th Ed. Eds R.L. Stamper, M.F. Lieberman, M.V. Drake - St. Louis, 2009.
  17. Berger W.E. Betaxolol in patients with glaucoma and asthma // Am. J. Ophthalmol. - 1987. - Vol.103. - Р. 600-601.
  18. Bhatt R., Whittaker K.W., Appaswamy S et al. Prospective survey of adverse reactions to topical antiglaucoma medications in a hospital population/Eye. - 2005. - Vol. 19, N 4. - Р. 392-395.
  19. Block E.R., Rostand R.A. Carbonic anhydrase inhibition in glaucoma: hazard or benefit for the chronic lunger? / Surv. Ophthalmol. - 1978. - Vol. 23, N 3. - Р. 169-172.
  20. Bodner C., Ross S., Douglas G. et al. The prevalence of adult onset wheeze: longitudinal study / Br. Med. J. - 1997. - Vol.314, N 7083. - Р. 792-793.
  21. Böhm E., Fabel H. Changes in lung function following administration of eyedrops containing timolol, metipranolol, pindolol and pilocarpine in healthy probands and patients with mild bronchial asthma/ Klin. Wschr. - 1987. - Vol. 65, N 19. - Р. 920-924.
  22. Camras C.B. Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma: a six-month masked, multicenter trial in the United States. The United States Latanoprost Study Group/Ophthalmology. - 1996. - Vol. 103. - Р. 138-147.
  23. Charan N.B., Lakshminarayan S. Pulmonary effects of topical timolol. /Arch. Intern. Med. - 1980. - Vol. 140, N 6. - Р. 843-844.
  24. Connolly M.J. Obstructive airways disease: a hidden disability in the aged/Age and Ageing. - 1996. - Vol. 25, N 4. - Р. 265-267.
  25. Connolly M.J., Crowley J.J., Charan N.B. et al. Reduced subjective awareness of bronchoconstriction provoked by methacholine in elderly asthmatic and normal subjects as measured on a simple awareness scale. / Thorax. - 1992. - Vol. 47, N 6. - Р. 410-413.
  26. Curti P.C., Renovanz H.D. The effect of unintentional overdoses of pilocarpine on pulmonary surfactant in mice./Klin. Monatsbl. Augenheilk. - 1981. - Bd 179. - S. 113-115.
  27. Detry-Morel M.Side effects of glaucoma medications // Bull. Soc. Belge Ophtalmol. - 2006. - Vol. 299. - Р. 27-40.
  28. Diggory P., Cassels-Brown A., Fernandez C. Topical beta-blockade with intrinsic sympathomimetic activity offers no advantage for the respiratory and cardiovascular function of elderly people/ Age and Ageing. - 1996. - Vol. 25, N 6. - Р. 424-428.
  29. Diggory P., Cassels-Brown A., Vail A. et al. Avoiding unsuspected respiratory side-effects of topical timolol with cardioselective or sympathomimetic agents / Lancet. - 1995. - Vol. 345. - Р. 1604-1606.
  30. Diggory P., Franks W. Glaucoma: systemic side effects of topical medical therapy - a common and under recognized problem / J. Roy. Soc. Med. - 1994. - Vol. 87, N 10. - Р. 575-576.
  31. Diggory P., Heyworth P., Chau G. et al. Improved lung function tests on changing from topical timolol: non-selective beta-blockade impairs lung function tests in elderly patients / Eye. - 1993. - Vol. 7, N 5. - Р. 661-663.
  32. Diggory P., Heyworth P., Chau G. et al. Unsuspected bronchospasm in association with topical timolol - a common problem in elderly people: can we easily identify those affected and do cardioselective agents lead to improvement?//' Age and Ageing. - 1994. - Vol. 23. - Р. 17-21.
  33. Erkin E.F., Çelik P., Kayikçioğlu O. et al. Effects of latanoprost and betaxolol on cardiovascular and respiratory status of newly diagnosed glaucoma patients // Ophthalmologica. - 2006. - Vol. 220, N 5. - Р. 332-337.
  34. Gandolfi S.A., Chetta A., Cimino L. et al. Bronchial reactivity in healthy individuals undergoing long-term topical treatment with beta-blockers. /Arch Ophthalmol. - 2005. - Vol. 123, N 1. - Р. 35-38.
  35. Gerber S.L., Cantor L.B. Systemic side effects & interactions of glaucoma medications // Clinical Guide to Glaucoma Management Eds E.J. Higginbotham, D.A. Lee. - London, 2004. - Р. 123-145.
  36. Han J.A., Frishman W.H., Wu Sun S. et al. Cardiovascular and respiratory considerations with pharmacotherapy of glaucoma and ocular hypertension//' Cardiol. Rev. - 2008. - Vol. 16, N 2. - Р. 95-108.
  37. Harris L.S., Greinstein S.H., Bloom A.F. Respiratory difficulties with betaxolol /Am. J. Ophthalmol. - 1986. - Vol.102. - Р. 274-275.
  38. Hedner J., Everts B., Möller C.S. Latanoprost and respiratory function in asthmatic patients: randomized, double-masked, placebo-controlled crossover evaluation // Arch. Ophthalmol. -1999. - Vol. 117, N 10. - Р. 1305-1309.
  39. Hedner J., Svedmyr N., Lunde H., Mandahl A. The lack of respiratory effects of the ocular hypotensive drug latanoprost in patients with moderate-steroid treated asthma // Surv. Ophthalmol. - 1997. - Vol. 41, Suppl. 2. - Р. 111-115.
  40. Higginbotham E.J., Schuman J.S., Goldberg I. et al. One-year, randomized study comparing bimatoprost and timolol in glaucoma and ocular hypertension/Arch. Ophthalmol. - 2002. - Vol. 120. - Р. 1286-1293.
  41. Inan U.U., Ermis S.S., Orman A. et al. The comparative cardiovascular, pulmonary, ocular blood flow, and ocular hypotensive effects of topical travoprost, bimatoprost, brimonidine, and betaxolol //J. Ocul. Pharmacol. Ther. - 2004. - Vol. 20, N 4. - Р. 293-310.
  42. Jones F.L., Ekberg N.L. Exacerbation of asthma by timolol //N. Engl. J. Med. - 1979. - Vol. 301, N 5. - Р. 270.
  43. Kirwan J.F., Nightingale J.A., Bunce C., Wormald R. Do selective topical beta antagonists for glaucoma have respiratory side effects? /Br. J. Ophthalmol. - 2004. - Vol. 88, N 2. - Р. 196-198.
  44. Nelson W.L., Fraunfelder F.T., Sills J.M. et al. JN. Adverse respiratory and cardio-vascular events attributed to timolol ophthalmic solution, 1978-1985/Am. J. Ophthalmol. - 1986. - Vol. 102, N 5. - Р. 606-611.
  45. Nelson W.L., Kuritsky J.N. Early postmarketing surveillance of betaxolol hydrochloride, September 1985 - September 1986 // Am. J. Ophthalmol. - 1987. - Vol. 103. - P. 592.
  46. Netland P.A., Landry T., Sullivan E.K. et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension/Am. J. Ophthalmol. - 2001. - Vol. 132. - Р. 472-484.
  47. Nygaard H.A., Hvding G. Adverse effects of local use of beta-blockaders in glaucoma. A literature review and a survey of reports to the adverse drug reaction authority 1986-95 /Tidsskr. Norske Laegeforen. - 1997. - Vol. 117, N 14. - Р. 2019-2021.
  48. Ofner S., Smith T.J. Betaxolol in chronic obstructive pulmonary disease//' J. Ocul. Pharmacol. - 1987. - Vol. 3. - Р. 171-176.
  49. Passo M.S., Palmer E.A., Van Buskirk E.M. Plasma timolol in glaucoma patients'/ Ophthalmology. - 1984. - Vol. 91, N 11. - Р. 1361-1363.
  50. Physician’s Desk Reference for Ophthalmology. - 28th Ed. -Montvale, N. J., 1999.
  51. Pfeiffer N., Wahl J. Рros and cons of ocular hypotensive lipids 2004 // Glaucoma Therapy Current Issues and Controversies / Eds T., Shaarawy and J. Flammer. - London, 2004. - P. 116.
  52. Prince D.S., Carliner N.H. Respiratory arrest following first dose of timolol ophthalmic solution / Chest. - 1983. - Vol. 84. - Р. 640-641.
  53. Rengstorff R., Royston M. Miotic drugs: a review of ocular, visual, and systemic complications / Am. J. Optom. Physiol. Opt. - 1976. - Vol. 53, N 2. - Р. 70-80.
  54. Renwick D.S., Connolly M.J. Prevalence and treatment of chronic airways obstruction in adults over the age of 45/Thorax. - 1996. - Vol. 51, N 2. - Р. 164-168.
  55. Rockwood J.E. Medical management of glaucoma // Clinical Guide to Glaucoma Management Eds E.J. Higginbotham, D.A. Lee. - London, 2004. - Р. 107-122.
  56. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardioselective betablocker use in patients with reversible airway disease // Cochrane Database Syst. Rev. - 2001. - Vol. 2. - CD002992.
  57. Salpeter S.R., Ormiston T.M., Salpeter E.E. Cardioselective betablockers in patients with reactive airway disease. a meta-analysis. //Ann. Intern. Med. - 2002. - Vol. 137, N 9. - Р. 715-725.
  58. Salpeter S.R., Ormiston T.M., Salpeter E.E. et al. Cardioselective betablockers_for chronic obstructive pulmonary disease. a meta-analysis. /Respir. Med. - 2003. - Vol. 97, N 10. - Р. 1094-1101.
  59. Schoene R.B., Abuan T., Ward R.L., Beasley C.H. Effects oftopical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis /Am. J. Ophthalmol. - 1984. - Vol. 97. - Р. 86-92.
  60. Schoene R.B., Martin T.R., Charan N.B., French C.L. Timolol-induced bronchospasm in asthmatic bronchitis / J. A. M. A. -1981. - Vol. 245. - Р. 1460-1461.
  61. Shell J.W. Pharmacokinetics of topically applied ophthalmic drugs./Surv. Ophthalmol. - 1982. - Vol. 26. - Р. 207-218.
  62. Shields M.B. Cholinergic agents // Shields’ Textbook of Glaucoma. - Philadelphia, 2005. - Р. 501-508.
  63. Snape J.P., Waldock A. Spirometry for patients prescribed topical beta-blockers /Nurs. Stand. - 2000. - Vol. 15, N 4. - Р. 35-38.
  64. Stamper R.L., Wigginton S.A., Higginbotham E.J. Primary drug treatment for glaucoma: beta-blockers versus other medications. / Surv. Ophthalmol. - 2002. - Vol.47, N 1. - Р. 63-73.
  65. Stewart W.C., Garrison P.M.b-Blocker-induced complications and the patient with glaucoma. Newer treatments to help reduce systemic adverse events /Arch. Intern. Med. - 1998. - Vol. 158, N 3. - P. 221-226.
  66. Taniguchi T., Kitazawa Y. The potential systemic effect of topically applied betablockers in glaucoma therapy / Curr. Opin. Ophthalmol. - 1997. - Vol. 8 N 2. - P. 55-58.
  67. Terminology and Guidelines for glaucoma. 3rd Ed. - European Glaucoma Society, 2008.
  68. Valuck R.J., Perlman J.I., Anderson C., Wortman G.I. Co-prescribing of medications used to treat obstructive lung disease, congestive heart failure and depression among users of topical beta blockers: estimates from three US Veterans Affairs Medical Centers. / Pharmacoepidemiol. Drug Saf. - 2001. - Vol. 10, N 6. - Р. 511-516.
  69. Van Buskirk E.M., Weinreb R.N., Berry D.P. et al. Betaxolol in patients with glaucoma and asthma//Am. J. Ophthalmol. - 1986. - Vol.101. - Р. 531-534.
  70. Van der Valk R., Webers C.A., Schouten J.S. et al. Intraocular pressurelowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials // Ophthalmology. - 2005. - Vol. 112, N 7. - Р. 1177-1185.
  71. Vonwil A., Landolt M., Flammer J., Bachofen H. Bronchoconstrictive side effects of timolol eye drops in patients with obstructive lung disease / Schweiz. Med. Wschr. - 1981. - Bd 111, N 19. - S. 665-669.
  72. Vorwerk C., Thelen U., Buchholz P., Kimmich F. Treatment of glaucoma patients with insufficient intraocular pressure control: a survey of German ophthalmologists in private practice // Curr. Med. Res. Opin. - 2008. - Vol. 24, N 5. - Р. 1295-1301.
  73. Vuori M.L., Ali-Melkkila T. The effect ofbetaxolol and timolol on postoperative intraocular pressure. //Acta Ophthalmol. - 1993. -Vol. 71, N 4. - Р. 458-462.
  74. Vuori M.L., Ali-Melkkila T., Kaila T. et al. Beta 1-and beta 2-antagonist activity of topically applied betaxolol and timolol in the systemic circulation /Acta Ophthalmol. - 1993. - Vol. 71, N 5. - Р. 682-685.
  75. Vuori M.L., Ali-Melkkila T., Kaila T. et al. Plasma and aqueous humour concentrations and systemic effects of topical betaxolol and timolol in man/Acta Ophthalmol. - 1993. - Vol. 71, N 2. -Р. 201-206.
  76. Vuori M.L., Kaila T., Iisalo E., Saari K.M.Concentrations and antagonist activity of topically applied betaxolol in aqueous humou/Acta Ophthalmol. - 1993. - Vol. 71, N 5. - Р. 677-681.
  77. Waldock A., Snape J., Graham C.M. Effects of glaucoma medications on the cardiorespiratory and intraocular pressure status of newly diagnosed glaucoma patients // Br. J. Ophthalmol. - 2000. - Vol. 84. - P. 710-713.
  78. Weinreb R.N., Van Buskirk E.M., Cherniack R., Drake M.M. Longterm betaxolol therapy in glaucoma patients with pulmonary disease/Am. J. Ophthalmol. - 1988. - Vol. 106. - Р. 162-167.
  79. Zimmerman T.J., Wheeler T.M. Miotics: side effects and ways to avoid them// Ophthalmology. - 1982. - Vol. 89, N 1. - Р. 76-80.

Copyright (c) 2012 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies